Associate Editor

Peter Goadsby is Director, NIHR King’s Clinical Research Facility, Professor of Neurology, King’s College London, and Honorary Consultant Neurologist at King’s College Hospital and the Hospital for Sick Children, Great Ormond Street, London, U.K. He is a National Institute for Health and Care Research Senior Investigator. He is Professor emeritus of Neurology, University of California, Los Angeles.
Dr. Goadsby obtained his medical degree and neurology and neurophysiology training at the University of New South Wales (UNSW), Australia. He did post-doctoral work at Cornell and in Paris and post-graduate neurology training at Queen Square, London. He returned to UNSW and the Prince of Wales Hospital, Sydney, as a consultant neurologist and became an Associate Professor of Neurology. He was appointed Wellcome Senior Research Fellow at the Institute of Neurology, University College London and was Professor of Clinical Neurology and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. He was Professor of Neurology at the University of California, San Francisco.
Dr. Goadsby’s major research interests are in the basic mechanisms of primary headache disorders, such as migraine and cluster headache, in both experimental and clinical settings, and translating these insights into better management.
Aeon Biopharma; Abbvie; Aurene; CoolTech LLC; Dr Reddy’s; Eli-Lilly and Company; Epalex; Ipsen; Kallyope; Linpharma; Lundbeck; Orion Pharma; Pfizer; PureTech Health LLC; Shiratronics; Teva Pharmaceuticals; Vial
National Institute for Health and Care Research (U.K.); Corrigan Family Foundation